Alvine Pharmaceuticals Announces Positive Results From Phase 2a Trial of ALV003 in Celiac Disease Patients. Clinical Proof-of-Principle Achieved, Company to Begin Phase 2b Trial in 2012.
Posted by on October 24, 2011
Comments are closed.
